Home
Clinical Resources Search
PQI: Granisetron Transdermal System (Sancuso®) for Chemotherapy Induced Nausea and Vomiting

Granisetron Transdermal System (Sancuso®) for Chemotherapy Induced Nausea and Vomiting

Download PQI pdf 0.12MB

Last Updated: May 28, 2024

By: Latha Radhakrishnan, PharmD, BCPS, BCOP

About this PQI

The granisetron transdermal system is a 5-HT3 Receptor Antagonist (5-HT3 RA) that allows for an alternate medication delivery compared to oral or parenteral administration. The purpose of this PQI is to review appropriate patient identification and discuss clinical considerations for the use of granisetron in chemotherapy induced nausea and vomiting (CINV).

How to Use a Positive Quality Intervention (PQI)

Essentially, it’s a tool to improve patient care by sharing best practices in oncology care. Consider this standardized, peer-review clinical guidance to oncology healthcare teams, enabling you and your team to consistently deliver high-quality care to your patients.

Find a PQI

Find Similar Resources

All Resources

PQI PQI in Action PQI Podcast Toolkit Treatment Support Kit Video Nausea & Vomiting (N/V) Supportive Care

PQI

PQI: Ibrutinib Dosing Optimization

Author: Nick Bouchard, PharmD | Danielle Maciorowski, PharmD

Frequently Searched

Supported by

Granisetron Transdermal System (Sancuso®) for Chemotherapy Induced Nausea and Vomiting

About this PQI

How to Use a Positive Quality Intervention (PQI)

Find Similar Resources

PQI: Ibrutinib Dosing Optimization

PQI: Zanubrutinib (Brukinsa®) Patient Selection and Management

PQI: Zanubrutinib (Brukinsa ®) treatment for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

PQI: Vorasidenib (Voranigo®)

PQI in Action: Tremelimumab-actl (Imjudo®) Patient Management

PQI in Action: Tepotinib (Tepmetko®) for Non-Small Cell Lung Cancerwith MET Exon 14 Alterations

PQI in Action: Siltuximab (Sylvant®) in Patients with Idiopathic Multicentric Castleman Disease

PQI in Action: Isatuximab-irfc (Sarclisa®) in 1q21 Gain or Amplifications in Relapsed/Refractory Multiple Myeloma

The PQI Podcast S8 Ep 10: Operationalizing Bispecifics in the Community Setting

The PQI Podcast S3 Ep 11: Moffitt Clinical Pharmacy Program

The PQI Podcast S3 Ep 12: Health Disparities in Cancer Screenings

The PQI Podcast S3 Ep 13: The Importance of the Multidisciplinary Team

Readiness Tracker

Treatment Support Kit: Abemaciclib

Treatment Support Kit: Temozolomide

Treatment Support Kit: Tivozanib

Treatment Support Kit: Regorafenib

Video: Akynzeo® (Ready-to-Use Vial): A Step-by-Step Video Guide

Video: BRUKINSA® (Zanubrutinib) for Treatment of Relapsed or Refractory Marginal Zone Lymphoma

Video: Ibrutinib-Related Cardiac Toxicities: Management & Dose Modifications

Video: Neratinib for Extended Adjuvent Treatment of Adult Patients with Early-Stage HER2-Positive Breast Cancer (MIP)

PQI: Olanzapine (Zyprexa®) In Chemotherapy Induced Nausea and Vomiting

PQI: Netupitant/Fosnetupitant and Palonosetron (Akynzeo®) for Chemotherapy-Induced Nausea and Vomiting

PQI: Chemotherapy-Induced Nausea and Vomiting

The PQI Podcast S4 Ep 5: Role of Oncology Social Worker

The PQI Podcast S4 Ep 6 : Community Pharmacy and Ohio Board of Pharmacy

The PQI Podcast S4 Ep 9: Mental Illness and Burnout

The PQI Podcast S4 Ep 10: Oncology Wellness & Exercise

PQI in Action: Tremelimumab-actl (Imjudo®) Patient Management

The PQI Podcast S8 Ep 10: Operationalizing Bispecifics in the Community Setting

The PQI Podcast S3 Ep 11: Moffitt Clinical Pharmacy Program

The PQI Podcast S3 Ep 12: Health Disparities in Cancer Screenings